Lunai Bioworks and BrainStorm Announce Strategic Collaboration
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 28 2026
0mins
Lunai Bioworks' (LNAI) wholly owned subsidiary BioSymetrics and BrainStorm (BCLI) announced a strategic collaboration and Letter of Intent to jointly discover, validate, and advance novel therapeutic targets for neurological diseases. The collaboration is supported by a newly awarded grant from the LouLou Foundation. The collaboration combines BioSymetrics' AI-driven target discovery and in vivo zebrafish validation platform with BrainStorm Therapeutics' proprietary human-derived organoid systems to create an integrated translational engine for neurology drug discovery. The companies intend to generate high-confidence therapeutic programs designed for pharmaceutical partnering, licensing, and downstream development. Initial efforts will focus on rare genetic epilepsies and neurodegenerative diseases, including Parkinson's disease. As part of the collaboration, the companies are integrating BrainStorm's Parkinson's disease midbrain organoid foundation model with BioSymetrics' proprietary analysis of the Parkinson's Progression Markers Initiative dataset, to identify progression-associated biomarkers and high-confidence therapeutically actionable targets. The program is intended to support precision medicine strategies and accelerate the development of differentiated CNS therapeutics.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LNAI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LNAI
About LNAI
Lunai Bioworks, Inc is focused on AI-powered biodefense, drug discovery and advanced diagnostics. It is engaged in harnessing advanced computational biology and AI/machine learning to accelerate drug discovery, diagnostics and strengthen biosecurity capabilities. Its segments include RENB, BioSymetrics and RENC. The RENB segment is engaged in developing new immunotherapies to combat cancer. BioSymetrics is engaged in integrating multimodal data sources, including genomics, imaging, electronic health records, and other real-world evidence, to advance biomarker discovery, therapeutic development, and precision medicine. RENC is developing a predicative artificial intelligence-based diagnostic methodology for the use of earlier cancer detection. From high-resolution phenotyping to predictive disease modeling, the Company is pioneering a new era of precision diagnostics-where early detection, patient stratification, and therapeutic targeting converge into a single, adaptive platform.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Lunai Bioworks Regains Nasdaq Compliance After Reverse Split
- Reverse Split Implementation: Lunai Bioworks executed a 1-for-8 reverse stock split on May 22, reducing outstanding shares from approximately 36.3 million to 4.5 million, significantly boosting the share price to meet Nasdaq's minimum $1 requirement and thereby mitigating potential delisting risks.
- Compliance Status Restored: An SEC filing confirmed that Nasdaq acknowledged Lunai's regained compliance, lifting a key listing overhang, and if pre-market levels hold after the opening bell, LNAI shares could see their largest single-day gains in three months, further bolstering market confidence.
- Surge in Market Sentiment: Lunai's message volume on Stocktwits skyrocketed by nearly 20,000%, with investor sentiment shifting from neutral to 'extremely bullish', indicating strong optimism about its future performance and potentially driving the stock towards a $10 target.
- Monitoring Period Risks: Nasdaq has placed Lunai under a one-year monitoring period, during which any future non-compliance with the minimum bid price will disqualify the company from standard compliance plans, posing a potential threat to the stability of its stock price going forward.
See More
uniQure Shares Surge After FDA Softens Stance on Gene Therapy
- FDA Policy Shift: uniQure N.V. (QURE) shares surged 78.44% to $48.16 after the FDA accepted the 3-year analysis from its Phase I/II study as the primary basis for a Biologics License Application for AMT-130 in Huntington's disease, marking a significant regulatory milestone.
- Positive Cancer Vaccine Responses: Elicio Therapeutics Inc. (ELTX) reported that three patients in its Phase 2 AMPLIFY-7P study showed excellent responses to the experimental vaccine ELI-002 7P, leading to a 70.65% stock increase to $4.71, indicating potential for enhanced immunotherapy effectiveness.
- Key Company Developments: Lunai Bioworks (LNAI) saw its shares rise 40.06% to $4.00 as the CEO highlighted significant advancements, including a U.S. government defense contract and the development of an AI-driven precision neurology pipeline, positioning the company strategically in biotech and national security.
- Patent Application Boost: Polyrizon Ltd. (PLRZ) shares increased by 15.55% to $13.23 following the publication of a U.S. patent application for its nasal drug delivery technology, showcasing its innovative capabilities in the biotech sector and potential market impact.
See More
Lunai Bioworks Shares Surge Over 50% Following CEO Letter
- Significant Stock Surge: Lunai Bioworks shares rose over 50% following the CEO's letter outlining major advancements, indicating strong market confidence in the company's future, particularly in its biodefense platform.
- Defense Collaboration Project: The multi-year collaboration with the U.S. Department of Defense marks a significant shift from research to commercialization, utilizing Lunai's AI platform for chemical threat assessment, which is expected to provide a stable revenue stream for the company.
- Scientific Collaboration Network: By expanding its national security footprint through the Pathfinder Consortium, which includes leading institutions like Harvard University, Lunai enhances the scientific rigor of its biodefense work, further solidifying its industry position.
- Litigation Progress: Lunai is expediting its litigation related to alleged naked short selling, aiming to restore shareholder value by presenting evidence of significant failing-to-deliver activity, demonstrating the company's commitment to market integrity.
See More
Lunai Bioworks Strategic Update and Legal Action
- Defense Collaboration Opportunity: In April 2026, Lunai Bioworks secured its first multi-year defense collaboration with BioSymetrics to deploy its AI platform for chemical threat assessment, marking a significant commercial engagement with the U.S. government that is expected to generate stable revenue streams for the company.
- Research Alliance Formation: Lunai established the Pathfinder Consortium, bringing together leading institutions such as Harvard University and Brigham and Women's Hospital, reflecting the scientific rigor and national security relevance of its approach, which is anticipated to drive technological innovation and market expansion.
- Legal Action to Protect Shareholder Value: In May 2026, Lunai initiated legal action in Delaware against unidentified short sellers involved in the anomalous delivery of 29.6 million shares, with the court agreeing to expedite discovery to uncover market manipulation and restore shareholder value.
- Future Development Strategy: Lunai plans to advance its biodefense platform and neurology programs in the second half of 2026, execute its litigation strategy, and further solidify its market position in national security and public health through collaborations with government and scientific institutions.
See More
Lunai Bioworks Strategic Update and Legal Action
- Defense Collaboration Opportunity: In April 2026, Lunai Bioworks secured its first multi-year defense collaboration with BioSymetrics to deploy its AI platform for chemical threat assessment, which not only generates direct revenue but also establishes a commercial relationship with the U.S. government.
- Academic Alliance Formation: The company formed the Pathfinder Consortium, bringing together leading institutions like Harvard University and Brigham and Women's Hospital, reflecting Lunai's scientific rigor and national security relevance, which is expected to drive future technological innovation and market expansion.
- Neurology Progress: Lunai advances its precision neurology pipeline through the Augusta™ AI platform, recently receiving a $1.85 million NIH grant for alcohol use disorder research, demonstrating the company's potential in treating neurological diseases and enhancing its long-term value proposition.
- Legal Action to Protect Shareholder Value: In May 2026, Lunai initiated legal action in the U.S. District Court for Delaware to investigate unusual trading activities involving 29.6 million shares, aiming to expose market manipulation and restore shareholder value, showcasing the company's commitment to maintaining market integrity.
See More
CervoMed and Others See Significant Stock Gains
- CervoMed Clinical Progress: CervoMed's lead drug candidate Neflamapimod has completed enrollment in its Phase 2a trial in the US, with 24-week biomarker data expected in Q4 2023, which will significantly bolster its market potential in treating dementia.
- Conexeu Leadership Expansion: Conexeu Sciences expanded its board from six to nine members and appointed a Chief Commercial Officer to accelerate the development of its 3D-printed bioregenerative breast matrix, aiming to enhance market execution and growth potential.
- NeOnc International Regulatory Approval: NeOnc Technologies received regulatory clearance from the Department of Health - Abu Dhabi to initiate a Phase 2 trial of NEO212 for aggressive brain tumors, marking a significant step in its international development and enhancing its competitive position.
- Simulations Plus Acquisition Agreement: Simulations Plus has agreed to be acquired by Altaris for $375 million, with shareholders set to receive $18.50 per share, representing a premium, and the transaction is expected to close in Q4 2023, providing new capital and resources for future growth.
See More
Lunai Bioworks Regains Nasdaq Compliance After Reverse Split
- Reverse Split Implementation: Lunai Bioworks executed a 1-for-8 reverse stock split on May 22, reducing outstanding shares from approximately 36.3 million to 4.5 million, significantly boosting the share price to meet Nasdaq's minimum $1 requirement and thereby mitigating potential delisting risks.
- Compliance Status Restored: An SEC filing confirmed that Nasdaq acknowledged Lunai's regained compliance, lifting a key listing overhang, and if pre-market levels hold after the opening bell, LNAI shares could see their largest single-day gains in three months, further bolstering market confidence.
- Surge in Market Sentiment: Lunai's message volume on Stocktwits skyrocketed by nearly 20,000%, with investor sentiment shifting from neutral to 'extremely bullish', indicating strong optimism about its future performance and potentially driving the stock towards a $10 target.
- Monitoring Period Risks: Nasdaq has placed Lunai under a one-year monitoring period, during which any future non-compliance with the minimum bid price will disqualify the company from standard compliance plans, posing a potential threat to the stability of its stock price going forward.
See More
uniQure Shares Surge After FDA Softens Stance on Gene Therapy
- FDA Policy Shift: uniQure N.V. (QURE) shares surged 78.44% to $48.16 after the FDA accepted the 3-year analysis from its Phase I/II study as the primary basis for a Biologics License Application for AMT-130 in Huntington's disease, marking a significant regulatory milestone.
- Positive Cancer Vaccine Responses: Elicio Therapeutics Inc. (ELTX) reported that three patients in its Phase 2 AMPLIFY-7P study showed excellent responses to the experimental vaccine ELI-002 7P, leading to a 70.65% stock increase to $4.71, indicating potential for enhanced immunotherapy effectiveness.
- Key Company Developments: Lunai Bioworks (LNAI) saw its shares rise 40.06% to $4.00 as the CEO highlighted significant advancements, including a U.S. government defense contract and the development of an AI-driven precision neurology pipeline, positioning the company strategically in biotech and national security.
- Patent Application Boost: Polyrizon Ltd. (PLRZ) shares increased by 15.55% to $13.23 following the publication of a U.S. patent application for its nasal drug delivery technology, showcasing its innovative capabilities in the biotech sector and potential market impact.
See More
Lunai Bioworks Shares Surge Over 50% Following CEO Letter
- Significant Stock Surge: Lunai Bioworks shares rose over 50% following the CEO's letter outlining major advancements, indicating strong market confidence in the company's future, particularly in its biodefense platform.
- Defense Collaboration Project: The multi-year collaboration with the U.S. Department of Defense marks a significant shift from research to commercialization, utilizing Lunai's AI platform for chemical threat assessment, which is expected to provide a stable revenue stream for the company.
- Scientific Collaboration Network: By expanding its national security footprint through the Pathfinder Consortium, which includes leading institutions like Harvard University, Lunai enhances the scientific rigor of its biodefense work, further solidifying its industry position.
- Litigation Progress: Lunai is expediting its litigation related to alleged naked short selling, aiming to restore shareholder value by presenting evidence of significant failing-to-deliver activity, demonstrating the company's commitment to market integrity.
See More
Lunai Bioworks Strategic Update and Legal Action
- Defense Collaboration Opportunity: In April 2026, Lunai Bioworks secured its first multi-year defense collaboration with BioSymetrics to deploy its AI platform for chemical threat assessment, marking a significant commercial engagement with the U.S. government that is expected to generate stable revenue streams for the company.
- Research Alliance Formation: Lunai established the Pathfinder Consortium, bringing together leading institutions such as Harvard University and Brigham and Women's Hospital, reflecting the scientific rigor and national security relevance of its approach, which is anticipated to drive technological innovation and market expansion.
- Legal Action to Protect Shareholder Value: In May 2026, Lunai initiated legal action in Delaware against unidentified short sellers involved in the anomalous delivery of 29.6 million shares, with the court agreeing to expedite discovery to uncover market manipulation and restore shareholder value.
- Future Development Strategy: Lunai plans to advance its biodefense platform and neurology programs in the second half of 2026, execute its litigation strategy, and further solidify its market position in national security and public health through collaborations with government and scientific institutions.
See More
Lunai Bioworks Strategic Update and Legal Action
- Defense Collaboration Opportunity: In April 2026, Lunai Bioworks secured its first multi-year defense collaboration with BioSymetrics to deploy its AI platform for chemical threat assessment, which not only generates direct revenue but also establishes a commercial relationship with the U.S. government.
- Academic Alliance Formation: The company formed the Pathfinder Consortium, bringing together leading institutions like Harvard University and Brigham and Women's Hospital, reflecting Lunai's scientific rigor and national security relevance, which is expected to drive future technological innovation and market expansion.
- Neurology Progress: Lunai advances its precision neurology pipeline through the Augusta™ AI platform, recently receiving a $1.85 million NIH grant for alcohol use disorder research, demonstrating the company's potential in treating neurological diseases and enhancing its long-term value proposition.
- Legal Action to Protect Shareholder Value: In May 2026, Lunai initiated legal action in the U.S. District Court for Delaware to investigate unusual trading activities involving 29.6 million shares, aiming to expose market manipulation and restore shareholder value, showcasing the company's commitment to maintaining market integrity.
See More
CervoMed and Others See Significant Stock Gains
- CervoMed Clinical Progress: CervoMed's lead drug candidate Neflamapimod has completed enrollment in its Phase 2a trial in the US, with 24-week biomarker data expected in Q4 2023, which will significantly bolster its market potential in treating dementia.
- Conexeu Leadership Expansion: Conexeu Sciences expanded its board from six to nine members and appointed a Chief Commercial Officer to accelerate the development of its 3D-printed bioregenerative breast matrix, aiming to enhance market execution and growth potential.
- NeOnc International Regulatory Approval: NeOnc Technologies received regulatory clearance from the Department of Health - Abu Dhabi to initiate a Phase 2 trial of NEO212 for aggressive brain tumors, marking a significant step in its international development and enhancing its competitive position.
- Simulations Plus Acquisition Agreement: Simulations Plus has agreed to be acquired by Altaris for $375 million, with shareholders set to receive $18.50 per share, representing a premium, and the transaction is expected to close in Q4 2023, providing new capital and resources for future growth.
See More
